Q-omics provides the consensus-scored SEC22B4P profile across patient tissues and cancer cell-line models. SEC22B4P expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SEC22B4P is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, SEC22B4P RNA expression shows 18,103 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, COAD, and UVM as cancer lineages where SEC22B4P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SEC22B4P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SEC22B4P survival associations across molecular data types. SEC22B4P RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SEC22B4P RNA expression–survival associations across cancer types. High SEC22B4P expression shows favorable associations in KIRC, SKCM, PAAD, HNSC, UCS and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SEC22B4P RNA expression.
This table summarizes SEC22B4P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for SEC22B4P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SEC22B4P shows lower tumor expression in COAD, LUSC, KICH and UCEC and higher tumor expression in KIRC and CHOL. The COAD box plot shows higher SEC22B4P RNA expression in normal versus tumor tissue (log2 FC = −0.521, t-test p < 0.001).
This table shows molecular features associated with SEC22B4P in patient tissues and cancer cell lines. In patient samples, SEC22B4P shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
